Regulators, developers, and testing laboratories are exploring in silico models, transporter assays, and other options to better predict drug combination outcomes In the future, many drug–drug ...
Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from ...
This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations regarding CYP450 genetic testing in adult patients beginning treatment ...
Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs. So the ...
Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Evaluating Minority Participation in Radiation Oncology Clinical Trials and the Impact of COVID-19 on Enrollment in a Large Integrated Academic Satellite Network ...
Cytochromes P450 are a superfamily of enzymes containing heme as a cofactor that function as monooxygenases. Suppressed drug metabolism was identified in patients with various inflammatory conditions.
Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI). This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results